In short
This article explores the use of Capmatinib, a targeted therapy drug, in clinical trials for treating non-small cell lung cancer (NSCLC). Capmatinib is being studied, particularly in patients with MET exon 14 skipping mutations or MET amplification. The trials aim to evaluate its efficacy, safety, and potential benefits in various treatment settings, including as a first-line treatment and in combination with other therapies.
At a glance
- Drug Name
- Capmatinib (also known as INC280)
- Target Population
- NSCLC patients with MET exon 14 skipping mutations or high MET amplification
- Mechanism of Action
- Selective inhibitor of the cMET protein and MET signaling pathway
- Administration
- Oral tablets, typically 400 mg twice daily
- Key Efficacy Measures
- Overall response rate (ORR), Progression-free survival (PFS), Duration of response (DOR), Disease control rate (DCR), Overall survival (OS)
- Treatment Settings
- First-line, second-line, and later lines of therapy; monotherapy and combination therapy
- Notable Trials
- GEOMETRY mono-1, neoadjuvant/adjuvant studies, combination with immunotherapy
- Safety Assessments
- Monitoring of adverse events, laboratory tests, and vital signs
- Additional Investigations
- Pharmacokinetics, intracranial efficacy in brain metastases, quality of life measures
What is Capmatinib?
Capmatinib, also known by its brand name Tabrecta or research code INC280, is a medication used to treat a specific type of lung cancer called non-small cell lung cancer (NSCLC). It belongs to a class of drugs called targeted therapies, which are designed to attack cancer cells with specific genetic changes while minimizing damage to healthy cells.
How Capmatinib Works
Capmatinib works by targeting a specific protein called MET (mesenchymal-epithelial transition). In some lung cancers, the MET protein becomes overactive due to genetic changes, such as mutations in the MET gene or extra copies of the gene (called amplification). This overactivity can cause cancer cells to grow and spread.
Capmatinib is designed to block the activity of the MET protein. By doing so, it may slow down or stop the growth of cancer cells that depend on this protein to survive and multiply.
Conditions Treated by Capmatinib
Capmatinib is primarily used to treat advanced or metastatic non-small cell lung cancer (NSCLC) in patients whose tumors have specific genetic changes. These changes include:
- MET exon 14 skipping mutations: This is a change in the MET gene that causes part of the gene (exon 14) to be missing, leading to an overactive MET protein.
- MET amplification: This occurs when there are extra copies of the MET gene in the cancer cells.
Capmatinib is typically used in patients who have already tried other treatments or as a first-line treatment in some cases.
Effectiveness of Capmatinib
Clinical trials have shown that Capmatinib can be effective in treating NSCLC with MET alterations. Some key measures of its effectiveness include:
- Overall Response Rate (ORR): This is the percentage of patients whose tumors shrink or disappear after treatment. In some studies, the ORR for Capmatinib was significant, especially in patients with MET exon 14 skipping mutations.
- Duration of Response (DOR): This measures how long the tumor response lasts. Some patients have shown long-lasting responses to Capmatinib.
- Progression-Free Survival (PFS): This is the length of time during and after treatment that a patient lives with the disease without it getting worse.
It's important to note that the effectiveness can vary from person to person, and your doctor will consider your individual case when recommending treatment.
How Capmatinib is Administered
Capmatinib is taken orally in the form of tablets. The typical dose is 400 mg twice daily. Your doctor will provide specific instructions on how to take the medication, including whether to take it with or without food. It's important to follow these instructions carefully and to inform your healthcare team about any other medications you're taking.
Potential Side Effects
Like all medications, Capmatinib can cause side effects. Common side effects may include:
- Nausea and vomiting
- Fatigue
- Swelling in the legs or hands
- Decreased appetite
- Changes in liver function tests
Your healthcare team will monitor you for side effects and can help manage them if they occur. It's important to report any new symptoms or changes in your health to your doctor.
Ongoing Research
Research on Capmatinib is ongoing to better understand its effectiveness, safety, and potential use in different situations. Some areas of current research include:
- Using Capmatinib in combination with other cancer treatments.
- Studying its effectiveness in treating brain metastases (when lung cancer spreads to the brain).
- Using Capmatinib before and after surgery in certain stages of lung cancer.
- Evaluating its effectiveness in real-world settings outside of clinical trials.
These ongoing studies may lead to new ways of using Capmatinib to treat lung cancer in the future.